Zim Laboratories Ltd Q4 FY2024 Concall Summary

Key Takeaways

• A pivot quarter with recovery signs: Revenue rebounded sharply in Q4 as the currency crisis that had weighed on prior quarters began to ease, and the domestic business surged on institutional orders.
• New products are the growth engine: NIP and oral thin film (OTF) revenues, though still small at ₹11.2 crore combined in Q4, are expected to scale geometrically and could become a ₹150-200 crore segment over 3-4 years.
• Margins held ground despite a top-line drop: FY24 EBITDA fell 20.3% YoY, but net margin in absolute terms stayed flat, a sign that the mix shift toward complex, differentiated products is working.
• The pivot to regulated markets is now structural: The company is repositioning from an RoW/emerging markets player to a technology-led operator competing in the EU, a shift that has taken years and is now reflected in the facility, people, and regulatory culture.
• What to watch next quarter: The pace of marketing authorization (MA) grants in Europe, any further easing of currency shortages in emerging markets, and whether the domestic base holds at the new ₹65 crore level.

The Strategic Pivot

• From RoW to regulated markets: The company has repositioned itself from being largely an RoW and emerging market player to a regulated market operator specializing in complex products, a shift that involved overhauling the facility, products, people, and regulatory culture.
• EU certification as a moat: The company's EU-certified facility, which underwent a renewal inspection in January, gives it an advantage even in RoW and emerging markets as those regulators tighten standards and favour compliant operators.
• Business looks similar but the composition is changing: While the top line may appear flat or slow-growing, the underlying markets and products are shifting toward higher-value, differentiated offerings, a change that is showing up in margins.
• Margin focus over top-line obsession: Management explicitly prioritizes margins and EBITDA over revenue growth, arguing that top-line will follow if the value proposition is right.

Anwar Daud: "It's a pivot from being a largely an RoW and emerging market company, which means the whole canvas of the facility, the products, the kind of people we have, the kind of regulatory culture the company possesses. So this whole pivot has been there."

NIP & Oral Thin Films: The Growth Bet

• What NIP actually is: Novel Innovative Products are newer molecules just starting to come off patent, typically less than 10-20 years old, and very complex to make. They are not me-too products but me-better, bioequivalent versions that address problems in existing originator products through non-infringing delivery methods.
• The regulatory hurdle is also the barrier to entry: Convincing a regulator that a product is a me-better but bioequivalent is difficult, but that difficulty is precisely what lets the company stand out and command a premium.
• Filing momentum is building: The company filed 3 NIPs in FY24, bringing the total to 5 filings in the EU and 40 in Pharmerging and RoW markets. One NIP dossier was filed in Q4 across four EU countries: Spain, Portugal, Poland, and Italy.
• Revenue is early but the trajectory is geometric: NIP revenues were ₹7.3 crore in Q4 and ₹24.1 crore for FY24; OTF contributed ₹3.9 crore in Q4 and ₹13.1 crore for the full year. These are new products with 2-3 year registration cycles, and management expects incremental growth to become geometric once registrations come through.
• Concentration risk exists but will fade: Currently 4-5 products contribute to NIP revenue, with 2 driving 80%. As more products are registered and introduced across more geographies, this concentration will even out.
• Capacity is in place: Installed NIP capacity is sufficient to support a scenario where roughly 50% of revenue comes from NIP, with scope to increase capacity by up to 40%.

Anwar Daud: "It's always a little bit difficult to tell a regulator that this is not a me-too product. It is a me-better, but bioequivalent product. And those are the challenges, but it's interesting as well because otherwise, how would any company stand out from the crowd and be able to command some kind of a premium?"

Currency Crisis: Easing, Not Gone

• Q4 recovery was partly a catch-up: The quarter's strong performance was driven by an easing of the currency shortage that had plagued the prior three quarters, plus a spurt in NIP and oral film business that had been expected in the final quarter.
• Nutraceuticals took the hardest hit: The currency availability problem affected Nutraceuticals disproportionately because shipments were concentrated in affected markets. As currency issues ease, this segment should recover, though management expects only a partial return in the near term.
• PFI recovery will lag: While the finished formulation business continues to grow as part of the derisking strategy, the pre-formulation intermediate (PFI) segment may take longer to come back because currency shortages are easing only slowly.
• The problem is structural, not resolved: Management qualified that currency issues are easing but not gone, and that small economies in RoW and emerging markets will continue to face pressure until global interest rates and broader economic conditions unwind.

Anwar Daud: "I qualified my statement, I said the currency issues are easing out. They are not gone away. Unless the global economy itself - the interest rate and all those thing start unwinding. The currency issues in small economies, RoW and emerging markets will continue for some time."

Domestic & Asia ex-India: The Near-Term Drivers

• Domestic business hit a new scale: Domestic revenue reached ₹80.4 crore for FY24, up 35% YoY, driven by institutional orders for differentiated nutraceutical products and strategic partnerships with top Indian MNCs for NIP. Management pegs ₹65 crore as the new base.
• Asia ex-India surged: Revenue from Asia ex-India grew 74% YoY to ₹43.9 crore in Q4 and ₹123.5 crore for the full year, reflecting successful redirection of focus away from currency-hit markets.
• Growth will continue but at a slower pace: Management expects domestic growth to persist but not at the same percentage rate, implying the base effect will moderate the trajectory.

Regulatory & Filing Pipeline

• Dossier engine is running: The company filed 39 finished formulation dossiers in FY24, with 5 registrations received in Q4 and 26 for the full year. In oral dosage forms, 17 dossiers were submitted in Q4 and 51 for FY24, with 9 marketing authorizations received.
• European filings are in place: Five NIP products have been filed in Europe, some in multiple countries, and most are backed by sufficient marketing agreements from clients.
• MA grants are the bottleneck: Management expects some MAs to materialize this year, perhaps two to three, but cautioned that regulatory authorities are swamped with post-COVID backlogs and accelerated approvals cannot be predicted.
• More inspections are coming: Several more regulatory inspections have been triggered as the CapEx program progresses, and the EU inspection report with CAPA is expected to be filed later in the year.

Financial Position & Capital Allocation

• CapEx is peaking and will ease: The company spent ₹83.2 crore on CapEx in FY24, aimed at plant and equipment upgrades for EU and developed market supply. Management says CapEx is now easing as the desired build-out for the NIP portfolio nears completion.
• Debt will rise modestly before declining: About 25-30% of CapEx has been funded through borrowing, with the rest from internal accruals. Debt may initially rise around 10% as projects complete, then start coming down as repayment begins.
• Asset turns are the efficiency target: Management is targeting 2.5 times asset turns, a level the installed capacity can deliver, though present capacity is not yet fully utilized.
• R&D spend is steady at ~7%: The R&D team is stable and management is trying to expand it, with spend expected to remain in the same range.
• Inventory build was planned: The increase in inventory was driven by marketing planning; most was delivered in the last quarter and is now being stabilized at normal levels.

Zulfiquar Kamal: "So very rightly said, yes, we are looking at that number. And that is the ideal number which should go, because the present capacity is not yet fully utilized."

Guidance & Commitments

Key Metrics